Trevi Therapeutics Announces Initiation Of A Pivotal Study Of Nalbuphine ER In Uremic Pruritus
7/14/2014 7:09:52 AM
NEW HAVEN, Conn.--(BUSINESS WIRE)--Trevi Therapeutics, Inc. (“Trevi” or the “Company”), a clinical stage biotechnology company developing Nalbuphine ER for chronic pruritus conditions, today announced the first patient enrolled in the pivotal study of Nalbuphine ER in hemodialysis patients with uremic pruritus. The Company recently released data from its successfully completed Phase 1 trial in which Nalbuphine ER was well tolerated in hemodialysis patients and established proof-of-concept for Nalbuphine ER in treating uremic pruritus.
Help employers find you! Check out all the jobs and post your resume.
comments powered by